貝達藥業(300558.SZ):MCLA-129項目及第四代EGFR抑制劑BPI-361175項目的臨牀試驗在正常推進中
格隆匯7月7日丨有投資者向貝達藥業(300558.SZ)提問,“Mcla129和4代egfr已經進行兩年了,是不是都失敗了”
貝達藥業回覆稱,公司MCLA-129項目及第四代EGFR抑制劑BPI-361175項目的臨牀試驗在正常推進中。創新藥研發具有“週期長、投入大、風險高”的特徵,進入臨牀試驗之後,需要經歷安全性探索、療效探索、劑量探索的一系列過程,並根據臨牀反饋確定具體適應症,是一個漫長又充滿不確定性的過程。公司擁有優秀的醫學研發團隊,同時會借鑑已上市藥品的研發經驗,加快推進項目研發進度,如有重大進展會及時公吿披露。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.